Skip to search formSkip to main contentSkip to account menu
Activation of yeast PBS2 MAPKK by MAPKKKs or by binding of an SH3-containing osmosensor.
The role of mitogen-activated protein (MAP) kinase cascades in integrating distinct upstream signals was studied in yeast. Mutants that were not able to activate PBS2 MAP kinase kinase (MAPKK; Pbs2p)…
View on PubMed
Mutations in a protein tyrosine phosphatase gene (PTP2) and a protein serine/threonine phosphatase gene (PTC1) cause a synthetic growth defect in Saccharomyces cerevisiae
TLDR
It is demonstrated that although ptp2 has no obvious phenotype by itself, it has a profound effect on cell growth when combined with mutations in a novel protein phosphatase gene.
View on ASMUSA
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
TLDR
It is reported that genetic or pharmacological targeting of the oncogenic M UC1 subunit MUC1-C is sufficient to suppress PD-L1 expression in TNBC cells, and this finding offers a rationale to target MUC-C as a novel immunotherapeutic approach for TNBC treatment.
View on PubMed
Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.
TLDR
The study explored whether HDACI could induce the expression of costimulatory/adhesion molecules on acute myeloid leukemia (AML) cells, thereby effectively inducing tumor immunity and suggesting that the immunotherapeutic use of HDACIs may become a novel tool for treatment of AML.
View on PubMed
Histone deacetylase 3 associates with and represses the transcription factor GATA-2.
TLDR
This is the first demonstration that a tissue-specific transcription factor directly and selectively interacts with HDAC3 and HDAC5 among HDAC family members, and identifies GATA-2 as a nuclear target forHDAC3-mediated repression.
View on PubMed
Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer
TLDR
A master role for MUC1-C is uncovered in driving the induction of TWIST1, EMT, stemness, and drug resistance, and support MUC 1-C as a highly attractive target for inhibiting TNBC plasticity and progression.
View on Publisher
Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells
TLDR
It is shown that silencing MUC1-C is associated with decreases in xCT expression in TNBC cells and that targeting this novel MUC2-C/xCT pathway could represent a potential therapeutic approach for promoting TNBC cell death.
View PDF
MUC1-C INTEGRATES PD-L1 INDUCTION WITH REPRESSION OF IMMUNE EFFECTORS IN NON-SMALL CELL LUNG CANCER
TLDR
Findings support a previously unrecognized central role for MUC1-C in integrating PD-L1 activation with suppression of immune effectors and poor clinical outcome.
View on Nature
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
TLDR
It is demonstrated that upregulation of MUC1-C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and induces the neural BRN2 transcription factor, driving lineage plasticity through MYC andBRN2, inducing neuroendocrine features and stemness in prostate cancer.
View on Springer
Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
TLDR
The findings indicate that MUC1-C is a target for the treatment of TNBCs unresponsive to agents that inhibit anti-apoptotic members of the BCL-2 family.
View on Springer
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License